ストックスクリーナーアプリを入手
2.51
1.95%
-0.05
プレマーケット:
2.51
前日終値:
$2.56
開ける：
$2.53
24時間の取引高:
3.90M
Relative Volume:
0.69
時価総額：
$854.06M
収益：
-
当期純損益:
$-75.80M
株価収益率:
-7.1714
EPS:
-0.35
ネットキャッシュフロー:
$-68.07M
1週間 パフォーマンス:
+12.05%
1か月 パフォーマンス:
+22.44%
6か月 パフォーマンス:
-0.40%
1年 パフォーマンス:
-30.47%
1日の値動き範囲:
$2.47
$2.62
1週間の範囲:
$2.24
$2.62
52週間の値動き範囲:
$1.54
$3.97
Nuvation Bio Inc Stock (NUVB) Company Profile
名前
Nuvation Bio Inc
セクター
電話
(415) 754-3517
住所
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
NUVB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
2.51 | 799.62M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-23 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-03-27 | アップグレード | Jefferies | Hold → Buy |
| 2024-03-26 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-04-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | 開始されました | BMO Capital Markets | Outperform |
| 2021-03-08 | 開始されました | BTIG Research | Buy |
| 2021-03-08 | 開始されました | Cowen | Outperform |
| 2021-03-08 | 開始されました | Jefferies | Buy |
| 2021-03-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Nuvation Bio Inc (NUVB) 最新ニュース
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 - BioSpace
What drives Nuvation Bio Inc. stock priceConsistent high-performance stocks - Autocar Professional
Is Nuvation Bio Inc. a good long term investmentFree Consultation - Autocar Professional
Nuvation Bio Inc. Stock Analysis and ForecastFree Stock Index Interpretation - Autocar Professional
What analysts say about Nuvation Bio Inc. stockTremendous gains - jammulinksnews.com
Bullish Nuvation Bio Insiders Loaded Up On US$2.31m Of Stock - 富途牛牛
Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Breakthrough for IDH1 Mutant Glioma - TipRanks
Will Nuvation Bio Inc. stock benefit from interest rate changesLong Term Low Risk Growth - Newser
Is Nuvation Bio Inc. stock a good hedge against inflationFree Investing Community - Newser
Why Nuvation Bio Inc. stock attracts strong analyst attentionLow Risk Entry Points - beatles.ru
Nuvation Bio's Mysterious 5% Surge: A Deep Dive into the Unseen Drivers - AInvest
What makes Nuvation Bio Inc. stock price move sharplyIntraday Trade Ideas - Newser
How Nuvation Bio Inc. stock performs during market volatilityFree Top Growth Stock Recommendations - Newser
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy - MSN
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Nuvation Bio's 16% Surge: A Deep Dive Into the Unseen Drivers - AInvest
Nuvation Bio's 11% Spike: A Deep Dive into the Unseen Drivers - AInvest
Nuvation Bio’s 7% Surge: A Technical and Market Flow Deep-Dive - AInvest
Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Nuvation Bio’s SWOT analysis: IBTROZI approval boosts stock prospects By Investing.com - Investing.com Nigeria
Nuvation Bio’s SWOT analysis: IBTROZI approval boosts stock prospects - Investing.com
Positive week for Nuvation Bio Inc. (NYSE:NUVB) institutional investors who lost 31% over the past year - simplywall.st
RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating - MSN
JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans - MSN
Nuvation Bio Inc.(NYSE: NUVB) added to Russell 2500 Growth Index - MarketScreener
Nuvation Bio Inc.(NYSE: NUVB) added to Russell 2000 Growth Index - MarketScreener
Digging for Diamonds in Biotech: Why Insider Buys Signal Opportunity in Nuvation Bio and Ardelyx - AInvest
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Nuvation Bio stock rating reiterated at Market Outperform by Citizens JMP - Investing.com South Africa
Nuvation Bio's Taletrectinib Emerges as a Niche Oncology Leader with NCCN Endorsement - AInvest
Nuvation Bio (NUVB) Gains NCCN Endorsement for Taletrectinib in - GuruFocus
Nuvalent chases after Nuvation in ROS1 lung cancer - pharmaphorum
Nuvation Bio's Mysterious 10% Surge: A Technical & Market Flow Deep Dive - AInvest
Nuvation Bio jumps after insiders purchase shares worth over $1.1M - MSN
Nuvation Bio’s Mysterious 7% Surge: What’s Behind the Volatility? - AInvest
Wealth Enhancement Advisory Services LLC Buys Shares of 10,140 Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Insider Buying: Stacy Markel Acquires 10,000 Shares of Nuvation Bio Inc (NUVB) - GuruFocus
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price - GuruFocus
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price Target | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Target Price Revised Amid Commercial Shift | NUVB Stock News - GuruFocus
RBC Cuts Price Target on Nuvation Bio to $6 From $10, Keeps Outperform, Speculative Risk - MarketScreener
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - The Manila Times
Nuvation Bio Inc (NUVB) 財務データ
収益
当期純利益
現金流量
EPS
3.32%
1.57%
大文字化:
|
ボリューム (24 時間):